Want to see SE:INTEG.B full AI Analyst Report?
Top Page
Integrum AB Class B
(INTEG.B)
Select Model
Select Model
Rating:49Neutral
Price Target:
kr9.50
▼(-8.65% Downside)
Action:Reiterated
Date:09/18/26
The score is held down primarily by weak financial performance—unstable profitability, negative gross profit, and ongoing operating/free-cash-flow burn—despite a low-debt balance sheet. Technicals provide a partial offset with price trading above key moving averages and a positive MACD, but valuation support is limited given negative earnings and no stated dividend yield.
Positive Factors
Specialized osseointegration platform
Integrum operates in a specialized medtech niche with an implant platform designed to improve comfort and mobility versus traditional socket prostheses. This focused clinical use case can support durable demand as patients and healthcare providers seek alternatives for long-term prosthetic attachment.
Negative Factors
Severe current profitability pressure
Negative gross profit and deeply negative operating and net margins indicate that current sales are not covering the cost base. This limits internal funding capacity and means revenue growth may not translate into durable earnings until pricing, product economics, or expense discipline improves.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized osseointegration platform
Integrum operates in a specialized medtech niche with an implant platform designed to improve comfort and mobility versus traditional socket prostheses. This focused clinical use case can support durable demand as patients and healthcare providers seek alternatives for long-term prosthetic attachment.
Read all positive factors
Integrum AB Class B (INTEG.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr251.75M
Dividend YieldN/A
Average Volume (3M)69.54K
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue Growth1.43%
EPS Growth4.98%
CountrySE
Employees33
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.44
Shares Outstanding26,027,910
10 Day Avg. Volume89,417
30 Day Avg. Volume69,543
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)1.07
Price to Sales (P/S)2.01
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.68
Revenue Forecast (FY)kr209.00M
Integrum AB Class B Business Overview & Revenue Model
Company Description
Integrum AB (publ) focuses on the research, development, and global sale of advanced bone-anchored prosthetic solutions. A core offering is the Osseointegrated Prostheses for the Rehabilitation of Amputees (OPRA) implant system. This innovative bo...
How the Company Makes Money
Integrum makes money primarily by selling its osseointegration implant systems and associated components used in surgical implantation and long-term use. Revenue is generated from (1) product sales of implant hardware and related accessories suppl...
Integrum AB Class B Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 97.81M | 91.39M | 91.10M | 104.12M | 74.27M | 55.72M |
| Gross Profit | -1.75M | 63.23M | 75.38M | 91.26M | 60.84M | 46.56M |
| EBITDA | -25.61M | -39.62M | -35.50M | 8.76M | -20.24M | 2.60M |
| Net Income | -35.50M | -46.34M | -30.85M | 4.03M | -16.18M | 21.27M |
Balance Sheet | ||||||
| Total Assets | 199.15M | 203.60M | 203.25M | 164.86M | 165.17M | 180.44M |
| Cash, Cash Equivalents and Short-Term Investments | 15.01M | 19.06M | 39.60M | 16.90M | 41.92M | 75.34M |
| Total Debt | 2.74M | 3.17M | 4.84M | 6.42M | 7.92M | 580.89K |
| Total Liabilities | 24.96M | 31.59M | 25.38M | 22.07M | 21.64M | 20.70M |
| Stockholders Equity | 174.19M | 172.01M | 177.88M | 142.79M | 143.53M | 159.74M |
Cash Flow | ||||||
| Free Cash Flow | -43.10M | -57.96M | -50.59M | -24.37M | -36.50M | -49.55M |
| Operating Cash Flow | -33.67M | -41.02M | -37.70M | -12.74M | -25.10M | -20.28M |
| Investing Cash Flow | -16.44M | -16.94M | -12.89M | -11.63M | -11.40M | -29.27M |
| Financing Cash Flow | 37.92M | 37.43M | 73.29M | -648.54K | 3.08M | 117.23M |
Integrum AB Class B Technical Analysis
Positive
10.40
Price Trends
8.78
Positive
8.39
Positive
8.61
Positive
Market Momentum
0.26
Negative
55.11
Neutral
70.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:INTEG.B, the sentiment is Positive. The current price of 10.4 is above the 20-day moving average (MA) of 9.28, above the 50-day MA of 8.78, and above the 200-day MA of 8.61, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 55.11 is Neutral, neither overbought nor oversold. The STOCH value of 70.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:INTEG.B.
Integrum AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | kr67.30B | 25.21 | 8.88% | 1.92% | -3.56% | 79.60% | |
74 Outperform | kr56.74B | 89.66 | 30.26% | 0.38% | 13.94% | 5.70% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr560.70M | -65.63 | -2.84% | ― | -13.72% | 52.47% | |
49 Neutral | kr251.75M | -6.80 | -20.71% | ― | 1.43% | 4.98% | |
46 Neutral | kr433.13M | -3.94 | -37.43% | ― | 27.40% | 26.07% | |
42 Neutral | kr388.85M | -7.66 | ― | ― | -2.61% | -0.28% |
* Healthcare Sector Average
SE:INTEG.B
Integrum AB Class B
9.44
-4.66
-33.04%
SE:GETI.B
Getinge
247.10
46.04
22.90%
SE:SEZI
Senzime AB
2.76
-3.51
-55.99%
SE:BACTI.B
Bactiguard Holding AB
16.00
-4.40
-21.57%
SE:SECT.B
Sectra AB Class B
290.80
-12.78
-4.21%
SE:OSSD
OssDsign AB
3.52
-10.73
-75.32%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.